{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:59:46Z","timestamp":1790409586966,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejso.2026.112150","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:49:17Z","timestamp":1790264957000},"page":"112150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of histological subtype on outcomes of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-8449","authenticated-orcid":false,"given":"Pablo","family":"Lozano Lominchar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9601-0029","authenticated-orcid":false,"given":"Nathalie","family":"Santana Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Gonz\u00e1lez Bay\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-6538","authenticated-orcid":false,"given":"Xin-Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejso.2026.112150_bib1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ejso.2026.112150_bib2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"10.1016\/j.ejso.2026.112150_bib3","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.112150_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","article-title":"The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Deraco","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2026.112150_bib5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112150_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2026.112150_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/his.12807","article-title":"Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma","volume":"68","author":"Krasinskas","year":"2016","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ejso.2026.112150_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jtho.2021.09.012","article-title":"Molecular characterization of peritoneal mesotheliomas","volume":"17","author":"Offin","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112150_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41379-020-00688-4","article-title":"Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases","volume":"34","author":"Chapel","year":"2021","journal-title":"Mod Pathol"},{"issue":"15","key":"10.1016\/j.ejso.2026.112150_bib10","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2026.112150_bib11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2026.112150_bib12","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1245\/s10434-019-07803-z","article-title":"Malignant peritoneal mesothelioma: patterns of care and survival in the Netherlands: a population-based study","volume":"26","author":"de Boer","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.112150_bib13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejso.2026.112150_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol"},{"issue":"10272","key":"10.1016\/j.ejso.2026.112150_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112150_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.ejso.2026.112150_bib17","series-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"issue":"7650","key":"10.1016\/j.ejso.2026.112150_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"10.1016\/j.ejso.2026.112150_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random-effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejso.2026.112150_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.ejso.2026.112150_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.ejso.2026.112150_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12957-022-02688-x","article-title":"Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients","volume":"20","author":"Ma","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112150_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","article-title":"The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"23","author":"Kusamura","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112150_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1245\/s10434-012-2651-5","article-title":"A novel nomogram for peritoneal mesothelioma predicts survival","volume":"20","author":"Schaub","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112150_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1245\/s10434-017-6293-5","article-title":"Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal surface oncology group international registry","volume":"25","author":"Votanopoulos","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112150_bib26","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1245\/s10434-022-13061-3","article-title":"Long-term survival in patients treated with cytoreduction and heated intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center","volume":"30","author":"Valenzuela","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112150_bib27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/bjs5.50256","article-title":"Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting","volume":"4","author":"Brandl","year":"2020","journal-title":"BJS Open"},{"issue":"9","key":"10.1016\/j.ejso.2026.112150_bib28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ejso.2008.09.010","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma","volume":"35","author":"Yano","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2026.112150_bib29","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/PAS.0000000000000696","article-title":"A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype","volume":"40","author":"Valente","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ejso.2026.112150_bib30","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.21873\/anticanres.15776","article-title":"Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: outcomes and survival from an Australian centre","volume":"42","author":"Shamavonian","year":"2022","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.ejso.2026.112150_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275187","article-title":"A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma","volume":"17","author":"Wang","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejso.2026.112150_bib32","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1245\/s10434-024-15506-3","article-title":"Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study","volume":"31","author":"Ya\u015far","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2026.112150_bib33","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1245\/s10434-023-13528-x","article-title":"National practice patterns in malignant peritoneal mesothelioma: updates in management and survival","volume":"30","author":"Calthorpe","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112150_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1245\/s10434-023-13640-y","article-title":"Impact of perioperative systemic chemotherapy on survival for patients who have diffuse malignant peritoneal mesothelioma treated with CRS-HIPEC","volume":"31","author":"Chatterjee","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.112150_bib35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jso.27301","article-title":"Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: canadian practices and outcomes","volume":"128","author":"Deban","year":"2023","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.112150_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062288","article-title":"Peritoneal mesothelioma in a high volume peritoneal surface malignancies unit","volume":"12","author":"Pereira","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ejso.2026.112150_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"Janne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejso.2026.112150_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: translational evidence from two clinical trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326007699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:35:36Z","timestamp":1790408136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326007699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0748798326007699"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112150","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of histological subtype on outcomes of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112150"}}